Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026."The first quarter of 2026 reflects both strong execution and important strategic progress for Cantargia. We ...
Plaintiffs’ attorneys celebrate massive antitrust win against rising pharmaceutical costsBOSTON--(BUSINESS WIRE)--$TAK #antitrust--A class-action lawsuit against Takeda Pharmaceuticals USA Inc. on ...
SHELTON, CT / ACCESS Newswire / May 18, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the ...
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central ...
Aspera’s 11th ISS mission overall — now operating in microgravity to advance development of an oral Rebecsinib formulation ...
Series of high-quality acquisitions expands Clarion’s footprint in senior housing, outpatient medical, and inpatient ...
Research Describes the Potential of JCR’s Platform Technologies, Including JUST-AAV Gene Therapy, to Facilitate Delivery of Therapies to the Central Nervous System -HYOGO, Japan--(BUSINESS WIRE)--JCR ...
Binding term-sheet for a potential aggregate amount of up to USD 200 million and tiered royaltiesVILLEJUIF, France--(BUSINESS WIRE)--Regulatory News:Valerio Therapeutics (FR0010095596 – ALVIO), a ...
Category-specific honors identify client-rated leaders in data-ready EHRs, interoperability, enterprise imaging, cloud, cybersecurity, AI, advisory, analytics, clinical decision support and digital ...
The state-of-the-art facility enhances support for complex modalities across all phases of drug developmentKey factsThermo ...
Million in Q1 Net Income Driven by $2.2 Million Unrealized Gain on TAO HoldingsEight Months of Bittensor Subnet Diligence Has Sharpened the Company’s View of Where Its Operating Experience Can Be Most ...
Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results